High Triglyceridemia-Pipeline Review, H2 2015

High Triglyceridemia-Pipeline Review, H2 2015

  • Products Id :- GMDHC6859IDB
  • |
  • Pages: 109
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

High Triglyceridemia-Pipeline Review, H2 2015


Global Markets Direct's, 'High Triglyceridemia-Pipeline Review, H2 2015', provides an overview of the High Triglyceridemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of High Triglyceridemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for High Triglyceridemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the High Triglyceridemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

High Triglyceridemia Overview 9

Therapeutics Development 10

Pipeline Products for High Triglyceridemia-Overview 10

Pipeline Products for High Triglyceridemia-Comparative Analysis 11

High Triglyceridemia-Therapeutics under Development by Companies 12

High Triglyceridemia-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

High Triglyceridemia-Products under Development by Companies 17

High Triglyceridemia-Companies Involved in Therapeutics Development 19

Acasti Pharma Inc. 19

Allergan Plc 20

Alnylam Pharmaceuticals, Inc. 21

Arisaph Pharmaceuticals, Inc. 22

Astellas Pharma Inc. 23

AstraZeneca Plc 24


Cardax Pharmaceuticals, Inc. 26

Catabasis Pharmaceuticals, Inc. 27

CymaBay Therapeutics, Inc. 28

Daiichi Sankyo Company, Limited 29

Essentialis, Inc. 30

Isis Pharmaceuticals, Inc. 31

Jeil Pharmaceutical Co., Ltd. 32

Michigan Life Therapeutics, LLC 33

Novartis AG 34

Pharmena SA 35

Tekmira Pharmaceuticals Corp. 36

Thetis Pharmaceuticals LLC 37

High Triglyceridemia-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

ALN-AC3-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ALN-ANG-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ARI-3037MO-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AS-1708727-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

bezafibrate ER-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BioE-1115-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

CAT-2003-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

CDX-085-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

diazoxide choline CR-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

DS-8312-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

icosabutate-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ISIS-APOCIIILRx-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

MAT-9001-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MBX-8025-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

NKPL-66-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

omega-3-carboxylic acids-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

pradigastat sodium-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecule for Hypertriglyceridaemia-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecule for Hypertriglyceridemia-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecules for Dyslipidemia and Hypertriglyceridemia-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

TKM-HTG-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

TKMApoC-3-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

TP-101-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

TP-110-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

TRIA-662-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

volanesorsen sodium-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

High Triglyceridemia-Recent Pipeline Updates 81

High Triglyceridemia-Dormant Projects 98

High Triglyceridemia-Discontinued Products 100

High Triglyceridemia-Product Development Milestones 101

Featured News & Press Releases 101

Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 101

Mar 25, 2015: Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes 101

Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial 102

Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 102

Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 103

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 105

Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 105

May 06, 2014: FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia 106

Mar 31, 2014: Catabasis to Present CAT-2003 Data at the American College of Cardiology's 63rd Annual Scientific Session 107

Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia 107

Appendix 108

Methodology 108

Coverage 108

Secondary Research 108

Primary Research 108

Expert Panel Validation 108

Contact Us 108

Disclaimer 109

List of Tables

Number of Products under Development for High Triglyceridemia, H2 2015 10

Number of Products under Development for High Triglyceridemia-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Products under Development by Companies, H2 2015 (Contd..1) 18

High Triglyceridemia-Pipeline by Acasti Pharma Inc., H2 2015 19

High Triglyceridemia-Pipeline by Allergan Plc, H2 2015 20

High Triglyceridemia-Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 21

High Triglyceridemia-Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 22

High Triglyceridemia-Pipeline by Astellas Pharma Inc., H2 2015 23

High Triglyceridemia-Pipeline by AstraZeneca Plc, H2 2015 24

High Triglyceridemia-Pipeline by BASF SE, H2 2015 25

High Triglyceridemia-Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 26

High Triglyceridemia-Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015 27

High Triglyceridemia-Pipeline by CymaBay Therapeutics, Inc., H2 2015 28

High Triglyceridemia-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 29

High Triglyceridemia-Pipeline by Essentialis, Inc., H2 2015 30

High Triglyceridemia-Pipeline by Isis Pharmaceuticals, Inc., H2 2015 31

High Triglyceridemia-Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 32

High Triglyceridemia-Pipeline by Michigan Life Therapeutics, LLC, H2 2015 33

High Triglyceridemia-Pipeline by Novartis AG, H2 2015 34

High Triglyceridemia-Pipeline by Pharmena SA, H2 2015 35

High Triglyceridemia-Pipeline by Tekmira Pharmaceuticals Corp., H2 2015 36

High Triglyceridemia-Pipeline by Thetis Pharmaceuticals LLC, H2 2015 37

Assessment by Monotherapy Products, H2 2015 38

Number of Products by Stage and Target, H2 2015 40

Number of Products by Stage and Mechanism of Action, H2 2015 42

Number of Products by Stage and Route of Administration, H2 2015 44

Number of Products by Stage and Molecule Type, H2 2015 46

High Triglyceridemia Therapeutics-Recent Pipeline Updates, H2 2015 81

High Triglyceridemia-Dormant Projects, H2 2015 98

High Triglyceridemia-Dormant Projects (Contd..1), H2 2015 99

High Triglyceridemia-Discontinued Products, H2 2015 100

List of Figures

Number of Products under Development for High Triglyceridemia, H2 2015 10

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Products, H2 2015 16

Assessment by Monotherapy Products, H2 2015 38

Number of Products by Top 10 Targets, H2 2015 39

Number of Products by Stage and Top 10 Targets, H2 2015 39

Number of Products by Top 10 Mechanism of Actions, H2 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 41

Number of Products by Top 10 Routes of Administration, H2 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 43

Number of Products by Top 10 Molecule Types, H2 2015 45

Number of Products by Stage and Top 10 Molecule Types, H2 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Acasti Pharma Inc.

Allergan Plc

Alnylam Pharmaceuticals, Inc.

Arisaph Pharmaceuticals, Inc.

Astellas Pharma Inc.

AstraZeneca Plc


Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Daiichi Sankyo Company, Limited

Essentialis, Inc.

Isis Pharmaceuticals, Inc.

Jeil Pharmaceutical Co., Ltd.

Michigan Life Therapeutics, LLC

Novartis AG

Pharmena SA

Tekmira Pharmaceuticals Corp.

Thetis Pharmaceuticals LLC

High Triglyceridemia Therapeutic Products under Development, Key Players in High Triglyceridemia Therapeutics, High Triglyceridemia Pipeline Overview, High Triglyceridemia Pipeline, High Triglyceridemia Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com